000			01291 a2200373 4500
005			20250514184300.0
264		0	_c20040701
008			200407s 0 0 eng d
022			_a0026-556X
040			_aNLM _beng _cNLM
100	1		_aBohjanen, Kimberly A
245	0	0	_aNew biologic therapies for psoriatic disease. _h[electronic resource]
260			_bMinnesota medicine _cMar 2004
300			_a34-6 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAlefacept
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aClinical Trials as Topic
650	0	4	_aEtanercept
650	0	4	_aHumans
650	0	4	_aImmunoglobulin G _xadverse effects
650	0	4	_aImmunologic Factors _xadverse effects
650	0	4	_aImmunosuppressive Agents _xadverse effects
650	0	4	_aInfliximab
650	0	4	_aPsoriasis _ximmunology
650	0	4	_aReceptors, Tumor Necrosis Factor _xtherapeutic use
650	0	4	_aRecombinant Fusion Proteins _xadverse effects
650	0	4	_aT-Lymphocytes _xdrug effects
650	0	4	_aTreatment Outcome
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
700	1		_aPrawer, Steven E
773	0		_tMinnesota medicine _gvol. 87 _gno. 3 _gp. 34-6
999			_c14793905 _d14793905